Trump Signs Executive Order to Expand Psychedelics Access for Mental Health Treatment

President Donald Trump signed an executive order to expand access to certain psychedelic drugs for treating mental health disorders. The order states:

"Psychedelic drugs, including ibogaine compounds, show potential in clinical studies to address serious mental illnesses for patients whose conditions persist after completing standard therapy."

The directive instructs the Food and Drug Administration (FDA) to expedite reviews of qualifying psychedelics through the National Priority Voucher program, which aims for a one- to two-month review timeline. FDA Commissioner Mary Makary confirmed that three psychedelic compounds would be reviewed under the program.

The order also directs the FDA and the Drug Enforcement Administration (DEA) to allow patients access to psychedelics via the federal Right To Try Act, which permits individuals with life-threatening conditions to use investigational treatments. Additionally, the attorney general is tasked with expediting the rescheduling of psychedelics that have completed Stage 3 clinical trials.

Reactions and Historical Context

During the signing ceremony in the Oval Office, Trump joked about using psychedelics, saying:

"Can I have some, please? I'll take some."

The order marks a significant shift in drug policy discourse. As recently as 2015, such a scene would have been considered implausible. The evolution reflects growing mainstream acceptance of psychedelics, though the movement has advanced unevenly across jurisdictions.

State and Federal Psychedelics Policy Timeline

• 2019: Denver, Colorado, became the first U.S. city to decriminalize psilocybin mushrooms.
• 2020–2024: Three states—Colorado, Oregon, and New Mexico—passed policies allowing limited access to certain psychedelics. Several localities, including the District of Columbia, have deprioritized arrests for simple possession.
• 2018: The first Trump administration designated psilocybin as a "breakthrough therapy," though this did not significantly expand legal access.
• 2024: The FDA declined to approve MDMA as a PTSD treatment, despite advocacy from veterans groups.

While some states have liberalized laws, others, such as Massachusetts and California, have considered and rejected broader reforms. At the federal level, progress has been inconsistent, with psychedelics reform advancing in fits and starts.

Implications and Criticisms

Trump’s order is seen as both a policy advancement and a symbolic shift in the Overton Window, reflecting broader cultural openness to psychedelics. Advocates hope this momentum could mirror the rapid state-level legalization of marijuana.

However, critics note a contradiction: while the administration supports psychedelics access, it continues to aggressively prosecute drug trafficking through military interventions abroad. For example, the U.S. military has been involved in operations targeting suspected drug trafficking networks.